Does drug particle size matter? a study puts prifetrastat to the test

NCT ID NCT07721402

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study is testing whether changing the particle size of the experimental drug prifetrastat affects how much of it enters the bloodstream. Healthy volunteers will receive a single dose of prifetrastat in one of several tablet formulations with different particle sizes, then after a break, a second dose of a different formulation. By comparing blood levels, researchers hope to learn whether particle size influences drug absorption, processing, and elimination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: prifetrastat tablets with different particle sizes
What this could lead to: If particle size does not affect absorption, it could simplify manufacturing of prifetrastat. If it does, the results could guide future formulation development.
What could go wrong: This is a very early Phase 1 study with only 32 healthy participants, so results may not predict effects in patients or with repeated dosing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Pfizer Clinical Research Unit - Brussels
RECRUITING

Brussels, Bruxelles-capitale, Région de, B-1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.